Mereo BioPharma Group plc (AIM:MPH)
London · Delayed Price · Currency is GBP · Price in GBX 26.50
-0.50 (-1.85%)
At close: Dec 17, 2020
Mereo BioPharma Group Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | 0.5 | - | 10 | - | 49.37 | |
Revenue Growth | - | - | - | - | - | - |
Cost of Revenue | 0 | 0.13 | - | 2.57 | -1.15 | 24.25 |
Gross Profit | -0 | 0.37 | - | 7.43 | 1.15 | 25.13 |
Selling, General & Admin | 19.48 | 23.01 | 26.43 | 18.42 | 26.11 | 21.57 |
Research & Development | 13.88 | 15.92 | 19.28 | 16.14 | 27.74 | 31.9 |
Other Operating Expenses | -0.3 | -0.3 | - | - | - | - |
Operating Expenses | 33.07 | 38.62 | 45.72 | 34.56 | 53.84 | 53.47 |
Operating Income | -33.07 | -38.26 | -45.72 | -27.14 | -52.7 | -28.35 |
Interest Expense | -0.09 | -0.26 | -1.37 | -2.88 | -4.18 | -5.11 |
Interest & Investment Income | 1.53 | 2.17 | 3.04 | 2.13 | 0.84 | 0 |
Currency Exchange Gain (Loss) | 3.01 | -6.34 | 1.21 | -2.35 | 2.72 | -1.29 |
Other Non Operating Income (Expenses) | 0.51 | 0.81 | -0.42 | 0.24 | 10.37 | 53.88 |
EBT Excluding Unusual Items | -28.1 | -41.88 | -43.25 | -30 | -42.94 | 19.13 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 0.15 |
Pretax Income | -28.1 | -41.88 | -43.25 | -30 | -42.94 | 19.28 |
Income Tax Expense | - | - | - | -0.53 | -0.72 | 2.05 |
Net Income | -28.1 | -41.88 | -43.25 | -29.47 | -42.22 | 17.23 |
Net Income to Common | -28.1 | -41.88 | -43.25 | -29.47 | -42.22 | 17.23 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 160 | 159 | 148 | 132 | 121 | 106 |
Shares Outstanding (Diluted) | 160 | 159 | 148 | 132 | 121 | 111 |
Shares Change | 2.30% | 7.77% | 12.16% | 9.33% | 8.63% | 63.82% |
EPS (Basic) | -0.18 | -0.26 | -0.29 | -0.22 | -0.35 | 0.16 |
EPS (Diluted) | -0.18 | -0.26 | -0.29 | -0.22 | -0.35 | -0.31 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -25.35 | -30.99 | -32.83 | -21.13 | -48.83 | -7.82 |
Free Cash Flow Per Share | -0.16 | -0.19 | -0.22 | -0.16 | -0.41 | -0.07 |
Gross Margin | - | 73.40% | - | 74.26% | - | 50.89% |
Operating Margin | - | -7651.40% | - | -271.36% | - | -57.42% |
Profit Margin | - | -8375.60% | - | -294.66% | - | 34.90% |
Free Cash Flow Margin | - | -6198.20% | - | -211.32% | - | -15.83% |
EBITDA | -32.42 | -37.64 | -45.13 | -26.57 | -52.52 | -28.25 |
EBITDA Margin | - | - | - | -265.70% | - | -57.22% |
D&A For EBITDA | 0.65 | 0.62 | 0.58 | 0.57 | 0.18 | 0.1 |
EBIT | -33.07 | -38.26 | -45.72 | -27.14 | -52.7 | -28.35 |
EBIT Margin | - | - | - | -271.36% | - | -57.42% |
Effective Tax Rate | - | - | - | - | - | 10.64% |